Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
Anisha Misra, Elitza S. Theel
Journal of Clinical Microbiology (2022) Vol. 60, Iss. 6
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)
Miller Jm, Matthew J. Binnicker, Sheldon Campbell, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 42
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
José Luís Piñana, Rodrigo Martino, Lourdes Vázquez, et al.
Bone Marrow Transplantation (2023) Vol. 58, Iss. 5, pp. 567-580
Open Access | Times Cited: 24
Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Małgorzata Mikulska, Hans H. Hirsch, et al.
Leukemia (2023) Vol. 37, Iss. 9, pp. 1933-1938
Open Access | Times Cited: 24
A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy
Penny L. Moore, T. Leighton, Julie Ostrowsky, et al.
Vaccine (2023) Vol. 41, Iss. 13, pp. 2101-2112
Open Access | Times Cited: 19
Testing for SARS-CoV-2: lessons learned and current use cases
Elitza S. Theel, James E. Kirby, Nira R. Pollock
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 5
Seroconversion and dynamics of IgG anti-SARS-CoV-2 antibodies during the pandemic: A two-month observation cohort study on the population of Sleman in Indonesia
Jajah Fachiroh, Septi Kurnia Lestari, Dewi Kartikawati Paramita, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0316360-e0316360
Open Access
SARS-CoV-2 neutralizing antibody determination after vaccination using spectrophotometric measurement of lateral flow immunochromatography
Jianglei Ma, Scott Kaniper, Yuliya Vabishchevich, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Clinical Significance of Neutralizing Antibodies in COVID-19: Implications for Disease Prognosis
Sudem Mahmutoğlu Çolak, Tuba İlgar, İlkay Bahçeci, et al.
Life (2025) Vol. 15, Iss. 3, pp. 429-429
Open Access
Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland—A multicentre cohort study
Baharak Babouee Flury, Sabine Güsewell, Thomas Egger, et al.
PLoS Medicine (2022) Vol. 19, Iss. 11, pp. e1004125-e1004125
Open Access | Times Cited: 23
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity
Zhaohui Cai, Raj Kalkeri, Mi Wang, et al.
Microorganisms (2024) Vol. 12, Iss. 6, pp. 1201-1201
Open Access | Times Cited: 3
SARS-CoV-2 membrane protein-specific antibodies from critically ill SARS-CoV-2–infected individuals interact with Fc receptor–expressing cells but do not neutralize the virus
Daniel Fernández-Soto, Paula Alexandra Reis Bueno, Urtzi Garaigorta, et al.
Journal of Leukocyte Biology (2024) Vol. 115, Iss. 5, pp. 985-991
Open Access | Times Cited: 2
T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy
Anthony T. Reder, Olaf Stüve, Stephanie Tankou, et al.
Multiple Sclerosis Journal (2022) Vol. 29, Iss. 6, pp. 648-656
Open Access | Times Cited: 12
Clinical symptoms of SARS‐CoV‐2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination—A prospective multicentre cohort of health professionals (SURPRISE study)
Philipp Köhler, Baharak Babouee Flury, Sabine Güsewell, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 6
Open Access | Times Cited: 7
Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients
Thijs W. Hoffman, Bob Meek, Ger T. Rijkers, et al.
Transplant Immunology (2022) Vol. 72, pp. 101599-101599
Open Access | Times Cited: 11
Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths
Miguel Á. Ortega, Cielo García‐Montero, Oscar Fraile‐Martínez, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 6, pp. 995-995
Open Access | Times Cited: 11
Durability of humoral and cell‐mediated immune response after SARS‐CoV‐2 mRNA vaccine administration
Anastasiya Mihaylova, Spaska Lesichkova, Marta Baleva, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 10
Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing
Kelly O’Shea, Charles F. Schuler, Jesse Chen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Humoral and Cellular Immune Response after Three Doses of Sinopharm [Vero Cell]-Inactivated COVID-19 Vaccine in Combination with SARS-CoV-2 Infection Leads to Hybrid Immunity
Marija Vukčević, K. Šerovic, Mateja Despot, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 1, pp. 122-122
Open Access | Times Cited: 1
Validation of a severe acute respiratory syndrome coronavirus 2 microneutralization assay for evaluation of vaccine immunogenicity
Stephanie Hamilton, Mingzhu Zhu, Shane Cloney-Clark, et al.
Journal of Virological Methods (2024) Vol. 327, pp. 114945-114945
Open Access | Times Cited: 1
Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variants
Léa Dépéry, Isabelle Bally, Axelle Amen, et al.
Microbiology Spectrum (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study
Fabrizio Nelli, Agnese Fabbri, Valentina Panichi, et al.
International Immunopharmacology (2022) Vol. 108, pp. 108774-108774
Open Access | Times Cited: 8
A performance comparison of two (electro) chemiluminescence immunoassays for detection and quantitation of serum anti‐spike antibodies according to SARS‐CoV‐2 vaccination and infections status
Jorge Camacho, Eliseo Albert, João Zulaica, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 7
Immunological Studies to Understand Hybrid/Recombinant Variants of SARS-CoV-2
Vivek P. Chavda, Toshika Mishra, Suneetha Vuppu
Vaccines (2022) Vol. 11, Iss. 1, pp. 45-45
Open Access | Times Cited: 7
Humoral response after a third and fourth dose of mRNA-based SARS-CoV-2 vaccine in previously seronegative kidney transplant recipients
Clara Brandstetter, Maria Haller, J.M. Berger, et al.
Wiener klinische Wochenschrift (2022) Vol. 134, Iss. 23-24, pp. 815-821
Open Access | Times Cited: 6
Extracellular Vesicle-Based SARS-CoV-2 Vaccine
Yasunari Matsuzaka, Ryu Yashiro
Vaccines (2023) Vol. 11, Iss. 3, pp. 539-539
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top